^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) + Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2129 Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
Published date:
11/02/2023
Excerpt:
We report the initial safety, efficacy and correlative analysis of acalabrutinib in combination with axicabtagene ciloleucel (axi-cel) in R/R B-cell lymphoma….We conducted a phase I/II, open-label trial (NCT04257578) involving adult patients meeting FDA-approved criteria for axi-cel; this included patients with R/R CD19+ large B-cell (LBCL) and follicular lymphoma (FL) with measurable disease....Acalabrutinib successfully bridged most patients in this trial when given concurrently with axi-cel and safely maintained high CR rates.
Trial ID:
